There are currently 2868 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/30/2025
Locations: Research Site, Houston, Texas
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Local Institution - 0220, Houston, Texas +1 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Recruiting
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/30/2025
Locations: Local Institution - 0020, Houston, Texas
Conditions: Agitation, Alzheimer Disease
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Recruiting
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Center for Oncology and Blood Disorders, Houston, Texas
Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Recruiting
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Cutaneous Malignant
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Recruiting
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Research Site, Houston, Texas
Conditions: Delayed Graft Function, DGF, Kidney Transplant
Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
Recruiting
The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/30/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Schizophrenia and Related Disorders
EASE: The Materna Prep Pivotal Study
Recruiting
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Vaginal Delivery, Pelvic Organ Prolapse
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: Texas Children's Hospital- Site Number : 8400002, Houston, Texas
Conditions: Type 1 Diabetes
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Recruiting
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Liver Associates of Texas, Houston, Texas
Conditions: Primary Biliary Cholangitis, PBC
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Houston AIDS Research Team CRS, Houston, Texas
Conditions: HIV-1-infection